PH25618A - Stabilised human protein preparation - Google Patents

Stabilised human protein preparation

Info

Publication number
PH25618A
PH25618A PH37498A PH37498A PH25618A PH 25618 A PH25618 A PH 25618A PH 37498 A PH37498 A PH 37498A PH 37498 A PH37498 A PH 37498A PH 25618 A PH25618 A PH 25618A
Authority
PH
Philippines
Prior art keywords
human protein
protein preparation
stabilised
agents
stabilised human
Prior art date
Application number
PH37498A
Other languages
English (en)
Inventor
Heinrich Woog
Werner Gruber
Hans-Jorg Markl
Fritz Demmer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of PH25618A publication Critical patent/PH25618A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PH37498A 1987-09-05 1988-09-02 Stabilised human protein preparation PH25618A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729863 DE3729863A1 (de) 1987-09-05 1987-09-05 Stabilisierte erythropoietin-lyophilisate

Publications (1)

Publication Number Publication Date
PH25618A true PH25618A (en) 1991-08-08

Family

ID=6335375

Family Applications (1)

Application Number Title Priority Date Filing Date
PH37498A PH25618A (en) 1987-09-05 1988-09-02 Stabilised human protein preparation

Country Status (29)

Country Link
US (1) US4992419A (cs)
EP (1) EP0306824B1 (cs)
JP (1) JPH0780782B2 (cs)
KR (1) KR960009929B1 (cs)
CN (1) CN1027224C (cs)
AT (1) ATE77556T1 (cs)
AU (1) AU610636B2 (cs)
CA (1) CA1330301C (cs)
CS (1) CS274681B2 (cs)
DD (1) DD273004A5 (cs)
DE (2) DE3729863A1 (cs)
DK (1) DK174811B1 (cs)
ES (1) ES2051806T3 (cs)
FI (1) FI93517C (cs)
GR (1) GR3005454T3 (cs)
HK (1) HK89495A (cs)
HU (1) HU202761B (cs)
IE (1) IE60310B1 (cs)
IL (1) IL87628A (cs)
LV (1) LV10178B (cs)
MX (1) MX12880A (cs)
NO (1) NO178687C (cs)
NZ (1) NZ225975A (cs)
PH (1) PH25618A (cs)
PL (1) PL157944B1 (cs)
PT (1) PT88417B (cs)
RU (2) RU2043118C1 (cs)
UA (2) UA26123A (cs)
ZA (1) ZA886528B (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0582933A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CN1222315C (zh) * 1996-12-24 2005-10-12 拜奥根有限公司 稳定的液体干扰素制剂
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
RU2152206C1 (ru) * 1997-05-22 2000-07-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Таблетированная форма рекомбинантного человеческого эритропоэтина для перорального применения и способ ее получения
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PT986644E (pt) * 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
RU2128517C1 (ru) * 1998-07-20 1999-04-10 Колобков Сергей Леонидович Стабилизированный водный раствор эритропоэтина
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
DK1181036T3 (da) * 1999-04-09 2008-11-24 Ortho Mcneil Pharm Inc Farmaceutiske sammensætninger af erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7253142B1 (en) 1999-09-08 2007-08-07 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
RU2182141C2 (ru) * 2000-03-20 2002-05-10 Братский государственный технический университет Композиция для изготовления легкобетонных изделий
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
EP2311492B1 (en) * 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
RU2191594C1 (ru) * 2001-04-03 2002-10-27 Григорян Седа Суреновна Средство и способ повышения резистентности к инфекции
RU2192882C1 (ru) * 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
BRPI0411114B8 (pt) 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
KR20070008519A (ko) * 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
GEP20156209B (en) * 2008-08-15 2015-01-12 Aironvud Farmasiutikalz Ink Linaclotide-containing formulations for oral administration
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011056850A2 (en) * 2009-11-03 2011-05-12 Ironwood Pharmaceuticals, Inc. Treatment of chronic constipation
KR101335765B1 (ko) 2010-01-19 2013-12-02 한미사이언스 주식회사 지속형 에리스로포이에틴 결합체의 액상 제제
EA201290799A1 (ru) 2010-02-17 2013-03-29 Айронвуд Фармасьютикалз, Инк. Лечение желудочно-кишечных расстройств
HUE046922T2 (hu) 2010-08-11 2020-03-30 Ironwood Pharmaceuticals Inc Linaklotid stabil formulációi
ES2614864T3 (es) 2011-08-17 2017-06-02 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos gastrointestinales
EA022327B1 (ru) * 2013-01-04 2015-12-30 Общество С Ограниченной Ответственностью "Рубикон" Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения
WO2015150930A1 (en) 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of conjugated erythropoietin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
ATE80306T1 (de) * 1985-03-06 1992-09-15 Survival Technology Mittel zur absorptionsverbesserung von proteinen.

Also Published As

Publication number Publication date
NO883926L (no) 1989-03-06
JPH0780782B2 (ja) 1995-08-30
HU202761B (en) 1991-04-29
CN1031801A (zh) 1989-03-22
DD273004A5 (de) 1989-11-01
MX12880A (es) 1993-12-01
HK89495A (en) 1995-06-16
DE3872334D1 (de) 1992-07-30
RU2100032C1 (ru) 1997-12-27
KR960009929B1 (ko) 1996-07-25
RU2043118C1 (ru) 1995-09-10
NO178687C (no) 1996-05-15
DE3729863A1 (de) 1989-03-16
DK483188D0 (da) 1988-08-30
GR3005454T3 (cs) 1993-05-24
EP0306824A2 (de) 1989-03-15
IE60310B1 (en) 1994-06-29
FI884051L (fi) 1989-03-06
IE882671L (en) 1989-03-05
NZ225975A (en) 1991-07-26
ATE77556T1 (de) 1992-07-15
FI93517B (fi) 1995-01-13
IL87628A (en) 1993-07-08
KR890004718A (ko) 1989-05-09
UA26855C2 (uk) 1999-12-29
EP0306824B1 (de) 1992-06-24
PT88417A (pt) 1989-07-31
JPS6471818A (en) 1989-03-16
LV10178B (en) 1995-04-20
PT88417B (pt) 1992-10-30
LV10178A (lv) 1994-10-20
IL87628A0 (en) 1989-01-31
HUT47863A (en) 1989-04-28
PL274485A1 (en) 1989-04-17
AU2173988A (en) 1989-04-27
CS590188A2 (en) 1990-12-13
DK483188A (da) 1989-03-06
NO178687B (no) 1996-02-05
CS274681B2 (en) 1991-09-15
ES2051806T3 (es) 1994-07-01
CN1027224C (zh) 1995-01-04
FI93517C (fi) 1995-04-25
FI884051A0 (fi) 1988-09-02
AU610636B2 (en) 1991-05-23
DK174811B1 (da) 2003-12-01
CA1330301C (en) 1994-06-21
EP0306824A3 (en) 1990-01-31
ZA886528B (en) 1989-05-30
US4992419A (en) 1991-02-12
NO883926D0 (no) 1988-09-02
PL157944B1 (en) 1992-07-31
UA26123A (uk) 1999-06-07

Similar Documents

Publication Publication Date Title
PH25618A (en) Stabilised human protein preparation
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
DE69740096D1 (de) Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
ZA91353B (en) Pharmaceutical and cosmetic compositions
IL131381A0 (en) Therapeutic agent for lymphatic tumors
EP0279619A3 (en) Production of proteins in active forms
TR199903192T2 (xx) Eritropoetin, de�i�tirilmi� hemoglobin i�eren farmasotik kombine m�stahzarlar.
EP0273800A3 (en) Hirudine variants, their use and preparation
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
EP0318948A3 (en) Cleavable immunoconjugates for the delivery and release of agents in native form
AU2958789A (en) Amino acid amides with a psychotropic action, processes for their preparation, agents containing them and their use
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
IL94218A0 (en) Peptides including a disulfide bond,their use in diagnosis and vaccine compositions containing them
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.
IT8819879A0 (it) Composizioni farmaceutiche atte all'impiego nella terapia dell'ipotensione arteriosa.